Table of contents

Key facts

Invented name
Active substance
Multivalent, live, recombinant, non-replicating in human cells, Modified Vaccinia Ankara vectored vaccine, expressing the EBOV Mayinga glycoprotein, the Sudan virus Gulu GP, the Marburg virus Musoke GP, and the Taï Forest virus nucleoprotein [MVA-BN-Filo]
Therapeutic area
  • Infectious diseases
  • Vaccines
Decision number
PIP number
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Prevention of Ebola virus disease
Route(s) of administration
Intramuscular use
Contact for public enquiries
Janssen Cilag International NV

Tel. +3214602111
E-mail: contact@Janssen-emea.com

Decision type
PM: decision on the application for modification of an agreed PIP


Related content

How useful was this page?

Add your rating